Phase 2 Study of Andecaliximab and Nivolumab for Gastroesophageal Junction or Gastric Cancer

For this phase 2 trial, researchers are evaluating the efficacy and safety of andecaliximab (GS-5745) and nivolumab vs nivolumab alone.
For this phase 2 trial, researchers are evaluating the efficacy and safety of andecaliximab (GS-5745) and nivolumab vs nivolumab alone.

Title: A Phase 2, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of GS-5745 Combined With Nivolumab Versus Nivolumab Alone in Subjects With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma1

Description: For this phase 2, randomized, 2-armed trial (ClinicalTrials.gov Identifier: NCT02864381), researchers are evaluating the efficacy and safety of andecaliximab (GS-5745) and nivolumab vs nivolumab alone among patients with unresectable or recurrent gastroesophageal junction or gastric cancer.

Patients must have inoperable, locally advanced or metastatic disease that progressed after at least 1 prior therapy.

The study has 2 arms: in the first, patients will receive andecaliximab 800 mg intravenously every 2 weeks plus intravenous nivolumab 3 mg/kg every 2 weeks; in the second, patients will receive intravenous nivolumab 3 mg/kg every 2 weeks.

The primary outcome is overall response rate; secondary outcomes include progression-free survival, overall survival, duration of response, and frequency/variety of adverse events.

For more study information, including detailed inclusion and exclusion criteria, study locations, and contact information, visit https://clinicaltrials.gov/ct2/show/NCT02864381.

Status: This study is open and recruiting participants as of April 7, 2017.

This study is sponsored by Gilead Sciences. Andecaliximab is a humanized monoclonal antibody that targets matrix metalloproteinase 9 (MMP-9).

Reference

  1. Clinicaltrials.gov. Andecaliximab combined with nivolumab versus nivolumab alone in adults with unresectable or recurrent gastric or gastroesophageal junction adenocarcinoma. NCT02864381. https://clinicaltrials.gov/ct2/show/NCT02864381. Accessed April 7, 2017.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters